ASSAY OF MATRIX METALLOPROTEASES TYPE-8 AND TYPE-9 BY ELISA IN HUMAN BREAST-CANCER

DUFFY MJ, BLASER J, DUGGAN C, MCDERMOTT E, OHIGGINS N, FENNELLY JJ, Tschesche H (1995)
BRITISH JOURNAL OF CANCER 71(5): 1025-1028.

Download
No fulltext has been uploaded. References only!
Journal Article | Original Article | Published | English

No fulltext has been uploaded

Author
; ; ; ; ; ;
Abstract
Results from model tumour systems suggest that either increased levels of certain metalloproteases (MMPs) or decreased levels of their inhibitors correlate with metastatic potential. In this study, levels of two MMPs, i.e. MMP-8 and -9, and their inhibitor tissue inhibitor of metalloprotease type 1 (TIMP-1) were measured by enzyme-linked immunosorbent assay in human breast tumours. Levels of MMP-8 and -9 correlated significantly with each other, but neither MMP correlated with urokinase plasminogen activator. Levels of both MMP-8 and -9 were also significantly related to levels of TIMP-1. In contrast, neither MMP correlated with plasminogen activator inhibitor. No relationship was found between MMP-8, MMP-9 or TIMP-1 and either tumour size or metastasis to axillary nodes. MMP-8 and -9 levels were inversely related to levels of oestrogen receptors. MMP-8 but not MMP-9 levels were also inversely correlated with progesterone receptor levels. It is concluded that the assay for MMP-8 and -9 described here will permit the evaluation of these proteases as prognostic markers in cancer.
Publishing Year
ISSN
eISSN
PUB-ID

Cite this

DUFFY MJ, BLASER J, DUGGAN C, et al. ASSAY OF MATRIX METALLOPROTEASES TYPE-8 AND TYPE-9 BY ELISA IN HUMAN BREAST-CANCER. BRITISH JOURNAL OF CANCER. 1995;71(5):1025-1028.
DUFFY, M. J., BLASER, J., DUGGAN, C., MCDERMOTT, E., OHIGGINS, N., FENNELLY, J. J., & Tschesche, H. (1995). ASSAY OF MATRIX METALLOPROTEASES TYPE-8 AND TYPE-9 BY ELISA IN HUMAN BREAST-CANCER. BRITISH JOURNAL OF CANCER, 71(5), 1025-1028. doi:10.1038/bjc.1995.197
DUFFY, M. J., BLASER, J., DUGGAN, C., MCDERMOTT, E., OHIGGINS, N., FENNELLY, J. J., and Tschesche, H. (1995). ASSAY OF MATRIX METALLOPROTEASES TYPE-8 AND TYPE-9 BY ELISA IN HUMAN BREAST-CANCER. BRITISH JOURNAL OF CANCER 71, 1025-1028.
DUFFY, M.J., et al., 1995. ASSAY OF MATRIX METALLOPROTEASES TYPE-8 AND TYPE-9 BY ELISA IN HUMAN BREAST-CANCER. BRITISH JOURNAL OF CANCER, 71(5), p 1025-1028.
M.J. DUFFY, et al., “ASSAY OF MATRIX METALLOPROTEASES TYPE-8 AND TYPE-9 BY ELISA IN HUMAN BREAST-CANCER”, BRITISH JOURNAL OF CANCER, vol. 71, 1995, pp. 1025-1028.
DUFFY, M.J., BLASER, J., DUGGAN, C., MCDERMOTT, E., OHIGGINS, N., FENNELLY, J.J., Tschesche, H.: ASSAY OF MATRIX METALLOPROTEASES TYPE-8 AND TYPE-9 BY ELISA IN HUMAN BREAST-CANCER. BRITISH JOURNAL OF CANCER. 71, 1025-1028 (1995).
DUFFY, MJ, BLASER, J, DUGGAN, C, MCDERMOTT, E, OHIGGINS, N, FENNELLY, JJ, and Tschesche, Harald. “ASSAY OF MATRIX METALLOPROTEASES TYPE-8 AND TYPE-9 BY ELISA IN HUMAN BREAST-CANCER”. BRITISH JOURNAL OF CANCER 71.5 (1995): 1025-1028.
This data publication is cited in the following publications:
This publication cites the following data publications:

24 Citations in Europe PMC

Data provided by Europe PubMed Central.

Matrix-metalloproteinases as targets for controlled delivery in cancer: An analysis of upregulation and expression.
Isaacson KJ, Martin Jensen M, Subrahmanyam NB, Ghandehari H., J Control Release 259(), 2017
PMID: 28153760
Reciprocal activation between MMP-8 and TGF-β1 stimulates EMT and malignant progression of hepatocellular carcinoma.
Qin G, Luo M, Chen J, Dang Y, Chen G, Li L, Zeng J, Lu Y, Yang J., Cancer Lett. 374(1), 2016
PMID: 26872724
Collagenase expression and activity in the stromal cells from giant cell tumour of bone.
Cowan RW, Mak IW, Colterjohn N, Singh G, Ghert M., Bone 44(5), 2009
PMID: 19442604
Clinical impact of MMP and TIMP gene polymorphisms in gastric cancer.
Kubben FJ, Sier CF, Meijer MJ, van den Berg M, van der Reijden JJ, Griffioen G, van de Velde CJ, Lamers CB, Verspaget HW., Br. J. Cancer 95(6), 2006
PMID: 16940985
Polymorphisms of the promoter regions of matrix metalloproteinases genes MMP-1 and MMP-9 in breast cancer.
Przybylowska K, Kluczna A, Zadrozny M, Krawczyk T, Kulig A, Rykala J, Kolacinska A, Morawiec Z, Drzewoski J, Blasiak J., Breast Cancer Res. Treat. 95(1), 2006
PMID: 16267613
Expression of matrix metalloproteinase-9 (gelatinase B) in gouty arthritis and stimulation of MMP-9 by urate crystals in macrophages.
Hsieh MS, Ho HC, Chou DT, Pan S, Liang YC, Hsieh TY, Lan JL, Tsai SH., J. Cell. Biochem. 89(4), 2003
PMID: 12858344
Expression of ADAM-9 mRNA and protein in human breast cancer.
O'Shea C, McKie N, Buggy Y, Duggan C, Hill AD, McDermott E, O'Higgins N, Duffy MJ., Int. J. Cancer 105(6), 2003
PMID: 12767059
Expression of proteinases and inhibitors in human breast cancer progression and survival.
Baker EA, Stephenson TJ, Reed MW, Brown NJ., MP, Mol. Pathol. 55(5), 2002
PMID: 12354933
Dynamics of metalloproteinase-2 and -9, TGF-beta, and uPA activities during normoxic vs. hyperoxic alveolarization.
Buckley S, Warburton D., Am. J. Physiol. Lung Cell Mol. Physiol. 283(4), 2002
PMID: 12225951
Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients.
Scorilas A, Karameris A, Arnogiannaki N, Ardavanis A, Bassilopoulos P, Trangas T, Talieri M., Br. J. Cancer 84(11), 2001
PMID: 11384099
Plasma metalloproteinase activity is enhanced in the euglobulin fraction of breast and lung cancer patients.
Farias E, Ranuncolo S, Cresta C, Specterman S, Armanasco E, Varela M, Lastiri J, Pallotta MG, Bal de Kier Joffe E, Puricelli L., Int. J. Cancer 89(4), 2000
PMID: 10956415
Proteolysis in human breast cancer.
Garbett EA, Reed MW, Stephenson TJ, Brown NJ., MP, Mol. Pathol. 53(2), 2000
PMID: 10889910
High levels of TIMP-2 correlate with adverse prognosis in breast cancer.
Remacle A, McCarthy K, Noel A, Maguire T, McDermott E, O'Higgins N, Foidart JM, Duffy MJ., Int. J. Cancer 89(2), 2000
PMID: 10756061
High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer.
McCarthy K, Maguire T, McGreal G, McDermott E, O'Higgins N, Duffy MJ., Int. J. Cancer 84(1), 1999
PMID: 9988231
The relationship between prognostic and predictive factors in the management of breast cancer.
Henderson IC, Patek AJ., Breast Cancer Res. Treat. 52(1-3), 1998
PMID: 10066087
Metalloproteinases and tissue inhibitors of metalloproteinases.
Toi M, Ishigaki S, Tominaga T., Breast Cancer Res. Treat. 52(1-3), 1998
PMID: 10066076
Hyaluronidase activity in gynaecological cancer tissues with different metastatic forms.
Tamakoshi K, Kikkawa F, Maeda O, Suganuma N, Yamagata S, Yamagata T, Tomoda Y., Br. J. Cancer 75(12), 1997
PMID: 9192986
Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma.
Sier CF, Kubben FJ, Ganesh S, Heerding MM, Griffioen G, Hanemaaijer R, van Krieken JH, Lamers CB, Verspaget HW., Br. J. Cancer 74(3), 1996
PMID: 8695357

32 References

Data provided by Europe PubMed Central.

Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family.
Stetler-Stevenson WG, Krutzsch HC, Liotta LA., J. Biol. Chem. 264(29), 1989
PMID: 2793861
Expression of metalloproteinases and their inhibitors in primary pulmonary carcinomas.
Urbanski SJ, Edwards DR, Maitland A, Leco KJ, Watson A, Kossakowska AE., Br. J. Cancer 66(6), 1992
PMID: 1457364
SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages.
Wilhelm SM, Collier IE, Marmer BL, Eisen AZ, Grant GA, Goldberg GI., J. Biol. Chem. 264(29), 1989
PMID: 2551898
M(r) 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer.
Zucker S, Lysik RM, Zarrabi MH, Moll U., Cancer Res. 53(1), 1993
PMID: 8416738

Export

0 Marked Publications

Open Data PUB

Web of Science

View record in Web of Science®

Sources

PMID: 7734294
PubMed | Europe PMC

Search this title in

Google Scholar